Real-world efficacy and safety of trastuzumab emtansine biosimilar (UJVIRA®) in early and metastatic HER2-positive breast cancer: a multicenter pooled retrospective analysis from India
Trastuzumab-emtansine (T-DM1), an antibody drug conjugate, is approved in the adjuvant (residual disease post-neoadjuvant chemotherapy) and metastatic settings for HER2-positive breast cancer. Real-world evidence on T-DM1 biosimilar from India remains sparse. During October 2021–July 2025, 101 cases treated with T-DM1...